Imagenetix, Inc. (IAGX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Imagenetix, Inc. (IAGX) with AI Score 47/100 (Weak). Imagenetix, Inc. develops and markets natural-based nutritional supplements and over-the-counter topical creams, with a focus on its primary product, Celadrin, for joint health. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Imagenetix, Inc. (IAGX) Healthcare & Pipeline Overview
Imagenetix, Inc. is a healthcare company focused on developing, formulating, and marketing proprietary and natural-based nutritional supplements, primarily Celadrin for joint health. The company operates within the specialty and generic drug manufacturing sector, distributing products through diverse channels and licensing its intellectual property.
Investment Thesis
Imagenetix, Inc. presents a unique investment profile within the specialty and generic drug manufacturing sector. The company's focus on natural-based nutritional supplements and over-the-counter products, particularly Celadrin, caters to the growing demand for alternative healthcare solutions. With a market capitalization of $0.00 billion and a negative P/E ratio of -0.13, the company's financial performance indicates potential challenges. However, a gross margin of 41.6% suggests a viable product portfolio. Growth catalysts include expanding distribution channels and strategic licensing agreements. Potential risks involve the company's small size, limited financial resources, and the highly competitive nature of the healthcare industry. The company's beta of -406.06 suggests an inverse correlation with the market.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 41.6% indicates potential profitability in product sales.
- Market Cap of $0.00B reflects the company's small size and limited market presence.
- Profit Margin of -2.6% suggests the company is currently operating at a loss.
- P/E Ratio of -0.13 indicates negative earnings, making valuation challenging.
- Beta of -406.06 suggests an inverse correlation with the market, potentially offering diversification benefits.
Competitors & Peers
Strengths
- Proprietary product formulations (e.g., Celadrin).
- Established distribution network.
- Focus on natural-based products.
- Intellectual property licensing opportunities.
Weaknesses
- Small company size and limited resources.
- Negative profit margin.
- High beta value indicating volatility.
- Dependence on a limited product portfolio.
Catalysts
- Upcoming: Potential new licensing agreements for Celadrin.
- Ongoing: Expansion of online distribution channels.
- Upcoming: Launch of new product formulations.
- Ongoing: Increased marketing efforts to drive brand awareness.
Risks
- Potential: Limited financial resources may hinder growth initiatives.
- Ongoing: Intense competition in the healthcare industry.
- Potential: Regulatory changes affecting the supplement industry.
- Ongoing: Dependence on a limited product portfolio.
- Potential: Product liability claims.
Growth Opportunities
- Expansion of Distribution Channels: Imagenetix can increase its market reach by expanding its distribution channels to include online retailers, pharmacies, and international markets. The global e-commerce market for health and personal care products is experiencing rapid growth, offering a significant opportunity for Imagenetix to increase sales and brand awareness. By leveraging online platforms and strategic partnerships, the company can tap into new customer segments and drive revenue growth. Timeline: Within the next 2 years.
- Strategic Licensing Agreements: Imagenetix can leverage its intellectual property by entering into strategic licensing agreements with other companies in the healthcare and wellness industry. Licensing agreements can provide a recurring revenue stream and expand the reach of Celadrin and other proprietary formulations. The market for licensing agreements in the healthcare sector is substantial, with numerous opportunities for companies with innovative products and technologies. Timeline: Ongoing.
- New Product Development: Imagenetix can drive growth by developing new products that address unmet needs in the healthcare market. The company can leverage its expertise in natural-based formulations to create innovative supplements and topical creams for various health conditions. The market for new and innovative healthcare products is constantly evolving, with consumers seeking effective and natural solutions for their health concerns. Timeline: Within the next 3 years.
- Targeted Marketing Campaigns: Imagenetix can enhance its brand awareness and drive sales through targeted marketing campaigns that focus on the benefits of Celadrin and other products. The company can leverage digital marketing channels, such as social media and search engine optimization, to reach its target audience and promote its products. The effectiveness of marketing campaigns can be measured through key performance indicators, such as website traffic, lead generation, and sales conversions. Timeline: Ongoing.
- International Expansion: Imagenetix can expand its market presence by entering new international markets. The global market for nutritional supplements and over-the-counter products is vast, with significant opportunities in emerging markets. By adapting its products and marketing strategies to local market conditions, Imagenetix can tap into new customer segments and drive revenue growth. Timeline: Within the next 5 years.
Opportunities
- Expansion into new markets and distribution channels.
- Development of new products and formulations.
- Strategic partnerships and licensing agreements.
- Growing demand for natural health products.
Threats
- Intense competition in the healthcare industry.
- Regulatory changes and compliance requirements.
- Potential product liability claims.
- Economic downturns affecting consumer spending.
Competitive Advantages
- Proprietary product formulations.
- Established brand recognition for Celadrin.
- Multi-channel distribution network.
- Intellectual property licensing agreements.
About IAGX
Founded in 1996 and based in San Diego, California, Imagenetix, Inc. operates within the healthcare sector, specifically in the realm of specialty and generic drug manufacturing. The company develops, formulates, and markets a range of proprietary and natural-based nutritional supplements, over-the-counter topical creams, and skincare products. Its flagship product, Celadrin, is a formulation designed to support joint health. In addition to its own product lines, Imagenetix, Inc. also generates revenue through licensing its intellectual property to third parties. The company employs a multi-channel distribution strategy, leveraging direct and mass marketing companies, nutritional and medical newsletters, and direct response radio and television to reach its target market. Imagenetix aims to provide consumers with natural alternatives for health and wellness, focusing on product efficacy and market accessibility. The company's size is relatively small, with only 5 employees, reflecting its focus on niche markets and specialized product offerings.
What They Do
- Develops proprietary nutritional supplements.
- Formulates natural-based health products.
- Markets over-the-counter topical creams.
- Specializes in skin care products.
- Offers Celadrin for joint health.
- Licenses intellectual property to third parties.
Business Model
- Develops and manufactures proprietary health products.
- Markets products through various distribution channels.
- Generates revenue through product sales.
- Licenses intellectual property for additional income.
Industry Context
Imagenetix, Inc. operates in the competitive specialty and generic drug manufacturing industry, which is characterized by increasing demand for over-the-counter and natural health products. The global nutritional supplements market is projected to reach billions of dollars by 2026, driven by rising health awareness and an aging population. Key competitors include both large pharmaceutical companies and smaller niche players. Imagenetix differentiates itself through its focus on proprietary formulations and natural ingredients, targeting consumers seeking alternative healthcare solutions. The company's success depends on its ability to innovate, effectively market its products, and navigate the complex regulatory landscape.
Key Customers
- Individuals seeking joint health solutions.
- Consumers interested in natural nutritional supplements.
- Customers of direct and mass marketing companies.
- Readers of nutritional and medical newsletters.
Financials
Chart & Info
Imagenetix, Inc. (IAGX) stock price: Price data unavailable
Latest News
No recent news available for IAGX.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IAGX.
Price Targets
Wall Street price target analysis for IAGX.
MoonshotScore
What does this score mean?
The MoonshotScore rates IAGX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Decky Goodrich
Managing Director
Decky Goodrich serves as the Managing Director of Imagenetix, Inc., overseeing the company's operations and strategic direction. With experience in managing small teams, Goodrich is responsible for guiding the company's development, formulation, and marketing of nutritional supplements and skincare products. His leadership is crucial in navigating the competitive healthcare market and driving the company's growth initiatives.
Track Record: Under Decky Goodrich's leadership, Imagenetix, Inc. has focused on maintaining its core product offerings, particularly Celadrin, and exploring licensing opportunities. The company has navigated the challenges of a competitive market while maintaining a focus on natural-based formulations. Goodrich's tenure has been marked by efforts to optimize distribution channels and manage the company's limited resources effectively.
IAGX OTC Market Information
The OTC Other tier, where Imagenetix trades, represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of higher tiers like OTCQX or OTCQB. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and the potential for fraud or manipulation. These companies are not required to adhere to the same stringent reporting standards as those listed on major exchanges like the NYSE or NASDAQ, leading to less transparency for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: Lack of regular financial reporting increases the risk of investing in IAGX.
- Low Liquidity: Limited trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Potential for Fraud or Manipulation: The OTC market is more susceptible to fraudulent activities and market manipulation.
- Lack of Regulatory Oversight: The absence of stringent regulatory oversight increases the risk of investing in IAGX.
- Going Concern Risk: Companies on the OTC Other tier may face going concern issues due to financial difficulties.
- Verify the company's legal status and registration.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any regulatory actions or legal proceedings.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Years in Operation: Imagenetix has been in operation since 1996, indicating some level of business stability.
- Proprietary Product Formulations: The company has proprietary product formulations, such as Celadrin, which could indicate a competitive advantage.
- Multi-Channel Distribution Network: Imagenetix utilizes a multi-channel distribution network, which can enhance its market reach.
- Focus on Natural-Based Products: The company's focus on natural-based products aligns with growing consumer demand for alternative healthcare solutions.
Imagenetix, Inc. Stock: Key Questions Answered
What does Imagenetix, Inc. do?
Imagenetix, Inc. is a healthcare company that develops, formulates, and markets proprietary and natural-based nutritional supplements, over-the-counter topical creams, and skincare products. Its primary product is Celadrin, a formulation for joint health. The company distributes its products through various channels, including direct marketing, newsletters, and medical professionals. Additionally, Imagenetix licenses its intellectual property to third parties, generating revenue through both product sales and licensing agreements. The company focuses on providing natural alternatives for health and wellness, targeting consumers seeking specialized health solutions.
What revenue streams does Imagenetix, Inc. have in healthcare?
Imagenetix, Inc.'s revenue streams primarily come from the sale of its proprietary and natural-based nutritional supplements and over-the-counter products, with Celadrin being a key contributor. Revenue is generated through various distribution channels, including direct and mass marketing companies, nutritional newsletters, and medical professionals. Additionally, the company earns revenue by licensing its intellectual property to third parties. The specific breakdown of revenue by product line and channel is not publicly available, but Celadrin and licensing agreements are significant components.
What are the main risks for IAGX?
The main risks for Imagenetix, Inc. include its small size and limited financial resources, which may hinder its ability to compete effectively in the healthcare industry. The company's negative profit margin indicates financial challenges, and its dependence on a limited product portfolio exposes it to market fluctuations. Additionally, regulatory changes in the supplement industry and potential product liability claims pose significant risks. As an OTC-listed company, IAGX faces additional risks related to liquidity, disclosure, and regulatory oversight.
What are the key factors to evaluate for IAGX?
Imagenetix, Inc. (IAGX) currently holds an AI score of 47/100, indicating low score. Key strength: Proprietary product formulations (e.g., Celadrin).. Primary risk to monitor: Potential: Limited financial resources may hinder growth initiatives.. This is not financial advice.
How frequently does IAGX data refresh on this page?
IAGX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IAGX's recent stock price performance?
Recent price movement in Imagenetix, Inc. (IAGX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary product formulations (e.g., Celadrin).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IAGX overvalued or undervalued right now?
Determining whether Imagenetix, Inc. (IAGX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IAGX?
Before investing in Imagenetix, Inc. (IAGX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC status and lack of comprehensive reporting.
- AI analysis is pending, which may provide further insights into the company's performance and prospects.